We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Analysis of Anti-inflammatory and Antioxidant Pathways in Lung Diseases by Haem Oxygenase-1 (HO-1) in Induced Sputum and Carbon Monoxide (CO) in Exhaled Air

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01140685
Recruitment Status : Unknown
Verified March 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Active, not recruiting
First Posted : June 9, 2010
Last Update Posted : June 9, 2010
Information provided by:
Tel-Aviv Sourasky Medical Center

Brief Summary:
This work will focus on the anti-inflammatory and antioxidant pathways in lung diseases by measuring HO-1 in induced sputum and CO in exhaled air in cases of four respiratory diseases, asthma, chronic obstructive pulmonary disease (COPD), occupational lung diseases (OLD) and interstitial lung disease (ILD).

Condition or disease Phase
Lung Diseases Phase 2

Study Type : Observational
Actual Enrollment : 70 participants
Observational Model: Case Control
Time Perspective: Prospective
Study Start Date : December 2009
Estimated Primary Completion Date : September 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. exhaled CO levels [ Time Frame: 2010-2011 ]

Biospecimen Retention:   Samples Without DNA
induced sputum, exhaled CO levels

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Fifty adult male and female patients who had been diagnosed with one or more of the four study diseases and referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center will be enrolled

Inclusion Criteria:

  • Male and female
  • Ages >/= 18 years
  • Diagnosed with one or more lung diseases
  • Referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01140685

Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Principal Investigator: Elizabeth Fierman, PHD Tel Aviv Sorasky Medical Center

Responsible Party: ELIZABETH FIERMAN, PHD, Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier: NCT01140685     History of Changes
Other Study ID Numbers: TASMC-10-LF-669-CTIL
First Posted: June 9, 2010    Key Record Dates
Last Update Posted: June 9, 2010
Last Verified: March 2010

Keywords provided by Tel-Aviv Sourasky Medical Center:
mucus-stimulated (induced sputum)
lung disease (asthma, COPD, ILD and OLD)
HO-1 (heme oxigenase-1)
oxidative stress
CO (carbon monoxide)
The oxidative stress in lung diseases

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Carbon Monoxide
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs